



Not for distribution or release in the United States

ASX ANNOUNCEMENT

15 December 2023

Expiry of escrow restrictions

15 December 2023 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) advises that, in accordance with Listing Rule 3.10A, 2,662,398 fully paid ordinary shares, which are currently classified as voluntarily restricted securities, will cease to be escrowed from 22 December 2023.

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine
Corporate Communications Manager
+61 439 492 955
jackson.paine@canngrouponlimited.com

For all other information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Head of Legal & Regulatory Affairs &
Company Secretary
Cann Group Limited
+61 3 9095 7088
steven.notaro@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com